Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 02/01/24 | 8-K | Current report filing |
|
   |
7 |
| 01/24/24 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
3 | |
| 01/19/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 01/08/24 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
5 | |
| 01/08/24 | 8-K | Current report filing |
|
|
26 |
| 12/19/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 11/21/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 11/20/23 | 144 | Filing for proposed sale of securities under Rule 144 |
|
3 | |
| 11/09/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
116 |
| 11/09/23 | 8-K | Current report filing |
|
|
36 |
